RXI Pharmaceuticals - Spotlight On Cosmetic Product Development
Edison | Apr 19, 2016 05:23AM ET
RXi Pharmaceuticals (NASDAQ:RXII) continues to make solid progress with its development pipeline. We anticipate one of two promising cosmeceutical candidates to enter human testing this year, moving forward on an expedited pathway for potential launch in 2019. We also expect data in H216 in all lead projects including RXI-109 in dermal scarring and in retinal scarring in wet AMD, and Samcyprone in cutaneous warts.
Cosmeceuticals move forward in skin appearance
In the latter part of 2015, RXi selected two treatment candidates to move forward on an expedited cosmeceuticals development pathway, RXI-231 (targeting tyrosinase to improve skin appearance) and RXI-185 (targeting collagenase for skin elasticity and anti-ageing). A successful cosmeceuticals launch could fetch sales of up to $150m and we expect at least one candidate to move into consumer testing by year end, for a targeted launch in 2019. RXi management has considerable expertise in cosmetic product development and we anticipate the completion of a series of marketing deals with large consumer product companies in coming years to bring in funds that can provide funding of RXi’s therapeutic pipeline.
To read the entire report Please click on the pdf File Below
RXI Pharmaceuticals - Spotlight On Cosmetic Product Development
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.